A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

NCT05091346 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Carcinoma, Hepatocellular
Colorectal Neoplasms

Interventions

DRUG: E7386
DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

Eisai Inc.

Collaborators

[object Object]